$268 Million

ADC Therapeutics

Initial Public Offering

Bookrunner, May 2020

ADC Therapeutics SA is a late clinical-stage biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors. The Company’s hematology franchise comprises three clinical-stage product candidates, loncastuximab tesirine (“Lonca” and previously known as ADCT-402), camidanlumab tesirine (“Cami” and previously known as ADCT-301) and ADCT-602. The Company’s solid tumor franchise comprises two clinical-stage product candidates, Cami and ADCT-601, and two pre-clinical product candidates, ADCT-901 and ADCT-701.

More Like This

Jul 2020
$144 Million

Initial Public Offering

Sole Bookrunner

View Details
Jun 2020
$244 Million

Initial Public Offering

Bookrunner

View Details
Jun 2020
$213 Million

Initial Public Offering

Bookrunner

View Details